AAN 2021 | Concomitant immunosuppressive therapy in gMG patients on the REGAIN extension study

James F. Howard, Jr., MD, FAAN, University of North Carolina School of Medicine, Chapel Hill, NC, discusses a post hoc analysis investigating concomitant immunosuppressive agents use in eculizumab-treated patients with refractory generalized myasthenia gravis (gMG) during the REGAIN open-label extension study (NCT02301624). Results showed that immunosuppressive therapy use by patients with previously refractory gMG decreased in the REGAIN extension study. Prof. Howard explains that all adjustments of concomitant immunosuppressive agents were the decision of study investigators, with no protocol-specified procedures. This interview took place during the American Academy of Neurology (AAN) 2021 Annual Meeting.